HMN-214 50 mg | Purity Not Available
TargetMol
HMN-214 (IVX-214) is a potent PLK1 inhibitor with an average IC50 of 0.12 μM.
More Information Supplier PageHMN-214
Search Results
HMN-214 10 mg | Purity Not Available
TargetMol
HMN-214 (IVX-214) is a potent PLK1 inhibitor with an average IC50 of 0.12 μM.
More Information Supplier PageHMN-214
LY 303511 5 mg | 99.91%
TargetMol
LY303511, an inactive analogue of LY294002, is a mTOR inhibitor and no inhibition for PI3-K.
More Information Supplier PageLY 303511
LY 303511 50 mg | 99.91%
TargetMol
LY303511, an inactive analogue of LY294002, is a mTOR inhibitor and no inhibition for PI3-K.
More Information Supplier PageLY 303511
LY 303511 25 mg | 99.91%
TargetMol
LY303511, an inactive analogue of LY294002, is a mTOR inhibitor and no inhibition for PI3-K.
More Information Supplier PageLY 303511
IRAK-1-4 Inhibitor I 10 mg | 100.00%
TargetMol
IRAK-1-4 Inhibitor I
IRAK-1-4 Inhibitor I 25 mg | 100.00%
TargetMol
IRAK-1-4 Inhibitor I
IRAK-1-4 Inhibitor I 5 mg | 100.00%
TargetMol
IRAK-1-4 Inhibitor I
INCB032304 50 mg | 100.00%
TargetMol
INCB032304 is an important pharmaceutical intermediate. It can be used in the preparation of Ruxolitinib phosphate (I008849), a janus kinase inhibitor, and in the preparation of Barretinib.
More Information Supplier PageINCB032304
INCB032304 25 mg | 100.00%
TargetMol
INCB032304 is an important pharmaceutical intermediate. It can be used in the preparation of Ruxolitinib phosphate (I008849), a janus kinase inhibitor, and in the preparation of Barretinib.
More Information Supplier PageINCB032304
